ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated ... Artificial intelligence isn’t science fiction anymore. It’s the revolution reshaping every industry ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover outperforming stocks and invest ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ ...

Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%.

If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify its ...